Creating a new generation of small molecule protease inhibitors

News

KalVista Announces Initiation of a Phase 1 Clinical Trial of KVD818 for the Treatment of Hereditary Angioedema

11 August 2016 Read more...

Carbylan Therapeutics and KalVista Pharmaceuticals Conference Call to Discuss Proposed Transaction

22 June 2016 Read more...

Registered Office: Building 227, Tetricus Science Park, Porton Down, SP4 0JQ, United Kingdom Registered in England. Registered No: 07543947